We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
176
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.2M 0.04%
22,046
– –
DOC icon
177
Healthpeak Properties
DOC
$15.2B
$1.2M 0.04%
45,500
– –
ARGX icon
178
argenx
ARGX
$54.6B
$1.15M 0.04%
15,188
-23,743
-61% -$2.11M
AFMD
179
DELISTED
Affimed
AFMD
$1.1M 0.04%
25,400
-137,079
-84% -$3.88M
NVAX icon
180
Novavax
NVAX
$1.22B
$1.07M 0.04%
28,550
– –
LMAT icon
181
LeMaitre Vascular
LMAT
$2.34B
$1.05M 0.04%
27,150
– –
HOLX
182
DELISTED
Hologic
HOLX
$801K 0.03%
19,546
– –
LIVN icon
183
LivaNova
LIVN
$4.45B
$779K 0.03%
6,287
– –
MTEM
184
DELISTED
Molecular Templates, Inc.
MTEM
$777K 0.03%
9,607
– –
ITCI
185
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$756K 0.03%
+34,850
New +$729K
LXRX icon
186
Lexicon Pharmaceuticals
LXRX
$1.04B
$747K 0.03%
+70,000
New +$802K
ECYT
187
DELISTED
Endocyte, Inc. Common Stock
ECYT
$746K 0.03%
+41,980
New +$721K
RYTM icon
188
Rhythm Pharmaceuticals
RYTM
$7.25B
$726K 0.03%
+24,890
New +$787K
ATNX
189
DELISTED
Athenex, Inc. Common Stock
ATNX
$708K 0.03%
+2,277
New +$801K
CYH icon
190
Community Health Systems
CYH
$391M
$706K 0.03%
203,935
– –
CDTX
191
DELISTED
Cidara Therapeutics
CDTX
$699K 0.03%
7,939
– –
XRN
192
Chiron Real Estate Inc
XRN
$516M
$691K 0.03%
14,680
– –
MRTX
193
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$640K 0.02%
+13,590
New +$757K
CLSD
194
DELISTED
Clearside Biomedical
CLSD
$508K 0.02%
5,511
– –
RMR icon
195
The RMR Group
RMR
$333M
$494K 0.02%
5,323
-2,118
-28% -$186K
LUMO
196
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$490K 0.02%
22,781
– –
ORKA
197
Oruka Therapeutics
ORKA
$5.9B
$454K 0.02%
3,756
– –
TLGT
198
DELISTED
Teligent, Inc
TLGT
$401K 0.01%
10,146
-80,490
-89% -$3.23M
ADYX
199
DELISTED
Adynxx Inc
ADYX
$375K 0.01%
27,500
– –
BLCM
200
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$370K 0.01%
6,000
– –
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.